Wednesday, July 8, 2026

biotech · Plaque Psoriasis · Rheumatoid Arthritis · CANF

Can Fite Biopharma

Can Fite Biopharma clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

10 Bareket Street, פ"ת, IL, RAMAT GAN, L3, USA HQ
9 Employees
Public company Type
CANF · NYSE Ticker
Company details
Status
Public
HQ
10 Bareket Street, פ"ת, IL, RAMAT GAN, L3, USA
Employees
9
Programs
20
Drugs
4
Patents
23
Intelligence · Clinical Programs

Can Fite Biopharma projects

7 ClinicalTrials.gov programs sponsored by Can Fite Biopharma.

Can Fite Biopharma has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CF101

    Can-Fite BioPharma

    Keratoconjunctivitis Sicca

    phase 3 small molecule completed

    2 trials
  2. CF101

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial
  3. CF101 1 mg

    Can-Fite BioPharma

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial
  4. CF101 2mg

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial
  5. Matching Placebo for Piclidenoson, Piclidenoson

    Can-Fite BioPharma

    Plaque psoriasis

    phase 3 small molecule active

    1 trial
  6. Namodenoson

    Can-Fite BioPharma

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial
  7. piclidenoson

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Can Fite Biopharma have?

7 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.